title: [Extracorporeal partial nephrectomy and auto-transplantation after presurgical targeted therapy with tyrosine kinase inhibitors for renal cell cancer].
abstract: A 74-year-old woman who had previously undergone left nephrectomy because of calculi was referred to our department with a right renal mass that was detected by computed tomography (CT) during treatment for pyelonephritis. Repeated CT showed a contrast-enhanced 4.7 cm tumor close to the renal sinus, and no metastatic lesion was detected. Sunitinib was administered as a presurgical therapy ; however, the patient experienced grade 3 neutropenia and thrombocytopenia, and sunitinib was discontinued. Sorafenib was administered 7 days after discontinuation of sunitinib ; however, the patient experienced febrile neutropenia and rash, and sorafenib was discontinued. Extracorporeal partial nephrectomy and auto-transplantation were performed 24 days after discontinuation of sorafenib. Though peri-graft abscess was suspected to be present and resolved by antibacterial therapy, severe complications were not experienced, and the patient did not require dialysis therapy after surgery. There was no evidence of recurrence at 30 months after the surgery.
authors.affiliation: The Department of Urology, Yamagata University Faculty of Medicine, Japan.
authors.forename: Hayato
authors.initials: H
authors.lastname: Nishida
authors.forename: Hidenori
authors.initials: H
authors.lastname: Kanno
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Hosoya
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Sakurai
authors.forename: Eita
authors.initials: E
authors.lastname: Mashima
authors.forename: Sei
authors.initials: S
authors.lastname: Naito
authors.forename: Hisashi
authors.initials: H
authors.lastname: Kawazoe
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Kato
authors.forename: Akira
authors.initials: A
authors.lastname: Nagaoka
authors.forename: Akiko
authors.initials: A
authors.lastname: Iwaba
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Yamakawa
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Tomita
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009392:Nephrectomy / Q000379:methods*; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D010671:Phenylurea Compounds / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D000077157:Sorafenib; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib